Who are mRNA-1273 Variant-containing Formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BioNTech - Pfizer COVID-19 vaccine, The Pfizer mRNA-based BNT162b2 vaccine, COMIRNATY - BioNTech Manufacturing GmbH, Spikevax bivalent Original/Omicron BA.1, Comirnaty Omicron XBB.1.5, COVID-19 mRNA vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mrna-1273-variant-containing-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

mRNA-1273 Variant-containing Formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mRNA-1273 Variant-containing Formulation (mRNA-1273 Variant-containing Formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mRNA-1273 Variant-containing Formulation (mRNA-1273 Variant-containing Formulation) — ModernaTX, Inc.. mRNA-1273 Variant-containing Formulation encodes instructions for cells to produce spike proteins from SARS-CoV-2 variants, triggering an immune response against those variants.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mRNA-1273 Variant-containing Formulation TARGET	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
BioNTech - Pfizer COVID-19 vaccine	BioNTech - Pfizer COVID-19 vaccine	University of Birmingham	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
The Pfizer mRNA-based BNT162b2 vaccine	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
COMIRNATY - BioNTech Manufacturing GmbH	COMIRNATY - BioNTech Manufacturing GmbH	Jens D Lundgren, MD	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Spikevax bivalent Original/Omicron BA.1	Spikevax bivalent Original/Omicron BA.1	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
Comirnaty Omicron XBB.1.5	Comirnaty Omicron XBB.1.5	Jules Bordet Institute	marketed	mRNA vaccine	SARS-CoV-2 spike protein (XBB.1.5 variant)
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

Pfizer · 12 drugs in this class
ModernaTX, Inc. · 11 drugs in this class
BioNTech SE · 5 drugs in this class
Jules Bordet Institute · 5 drugs in this class
Tan Tock Seng Hospital · 2 drugs in this class
Clover Biopharmaceuticals AUS Pty · 1 drug in this class
CanSino Biologics Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mRNA-1273 Variant-containing Formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/mrna-1273-variant-containing-formulation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing